#United States #California #Securities Class Action #Capricor Therapeutics #CAPR

Capricor Therapeutics Class Action Update

Investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) are cautioned to pay close attention to an upcoming deadline regarding a securities class action. The law firm Levi & Korsinsky, LLP, has announced that shareholders who purchased securities during the period from December 17, 2025, to July 26, 2026, may have significant claims to pursue. This notice serves to remind affected investors that motions for lead plaintiff in the case must be filed by September 28, 2026.

Background of the Class Action

The class action alleges that Capricor Therapeutics failed to adhere to its established protocols during its Phase 3 HOPE-3 trial for deramiocel, a treatment for Duchenne muscular dystrophy. According to the claims, important aspects of the trial design, including the statistical analysis and blinding protocols, were not followed as prescribed. Notably, the FDA indicated that the final protocol deviated from the original statistical analysis plan, calling into question the validity of trial outcomes.

On July 24, 2026, Capricor's stock price stood at $19.70 but subsequently plummeted to $4.19 by July 26, marking a staggering decline of approximately 78.7%. This drop resulted in a potential loss of $15.08 per share for investors who participated during the class period.

Legal Allegations

Key issues raised in the class action include:

• - Allegations that the company modified its pre-specified statistical analysis plan multiple times, which were not disclosed to investors.
• - Changes to key definitions and analytical approaches raised doubts about the integrity of the trial results, further compounded by significant adverse reactions in treated patients.
• - Public statements from Capricor highlighted statistically significant trial results while they obscured critical flaws and deviations in trial conduct, misleading investors about the likelihood of regulatory approval for deramiocel.

Joseph E. Levi, Esq., from the law firm, emphasized that the complaint raises serious doubts about the transparency of the information provided to investors during the trial process. If the allegations prove accurate, it suggests a significant breach of investor trust and regulatory guidelines.

Investor Eligibility

Investors who purchased Capricor securities within the noted timeframe and incurred losses may be eligible for recovery. Here are some critical points:

• - If you bought stocks during the identified class period, you could still join the lawsuit, even if you've since sold your shares at a loss.
• - To participate, it's recommended that investors gather necessary documentation, such as brokerage records substantiating purchases, sales, and the prices paid.
• - Contacting Levi & Korsinsky for a no-obligation evaluation can provide clarity on your eligibility for recovery.

Next Steps for Investors

Investors are urged to take action and review their brokerage documentation. Those interested in joining the action should reach out to Levi & Korsinsky by phone or email to discuss further steps:

• - Phone: (212) 363-7500
• - Email: [email protected]

Conclusion

With the deadline approaching, investors must act quickly to ensure their claims are heard. As the case unfolds in the Southern District of California, this represents a crucial moment for shareholders of Capricor Therapeutics seeking justice and recovery for potential losses due to alleged mismanagement and misrepresentation.

Act now to safeguard your rights as an investor and potentially partake in the recovery process. Remember, you have until September 28, 2026, to make your move.